Immune checkpoint inhibitors that block CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD1 (programmed death 1), or PD-L1 (programmed death-ligand 1) have demonstrated significant promise in the clinic across a range of cancer indications [1]. The gene discussed is CTLA4; the disease is cancer.